1. O-021Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2nd July 2019) Authors: Meyer, T; Finn, R; Kudo, M; Kang, Y; Yen, C; Galle, P; Llovet, J; Assenat, E; Brandi, G; Motomura, K; Okusaka, T; Hubner, R; Karwal, M; Baron, A; Ikeda, M; Liang, K; Wang, C; Widau, R; Schelman, W; Zhu, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). (2nd July 2019) Authors: Chau, I; Bendell, J; Soriano, A; Arkenau, H; Cultrera, J; Santana-Davila, R; Calvo, E; Tourneau, C Le; Zender, L; Mi, G; Schelman, W; Ferry, D; Herbst, R; Fuchs, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗